SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of first-line with
recombinant anti-EGFR monoclonal antibody#SCT200#and standard chemotherapy in patients with
Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.